e-learning
resources
Munich 2014
Wednesday, 10.09.2014
Clinical trials of drugs for respiratory diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Abediterol: Efficacy, safety and tolerability of the novel LABA in patients with persistent asthma
J. Beier, B. Seoane, E. Massana, G. De Miquel, H. Pujol, S. Ruiz (Wiesbaden, Germany; Barcelona, Spain)
Source:
International Congress 2014 – Clinical trials of drugs for respiratory diseases
Session:
Clinical trials of drugs for respiratory diseases
Session type:
Oral Presentation
Number:
4671
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Beier, B. Seoane, E. Massana, G. De Miquel, H. Pujol, S. Ruiz (Wiesbaden, Germany; Barcelona, Spain). Abediterol: Efficacy, safety and tolerability of the novel LABA in patients with persistent asthma. Eur Respir J 2014; 44: Suppl. 58, 4671
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Efficacy and safety of indacaterol acetate on ICS background therapy in asthma
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Once-daily tiotropium Respimat add-on to at least ICS in adult patients with symptomatic asthma: Pooled safety analysis
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Once-daily tiotropium respimat add-on to ICS±LABA improves control across asthma severities
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Tiotropium as add-on therapy to inhaled corticosteroids for patients with symptomatic asthma: Lung function and safety
Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD
Year: 2013
Efficacy and safety of abediterol, a long-acting beta
2
-adrenergic agonist (LABA); three phase II trials in asthma
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
Safety and tolerability of acute dosing of beta-blockers in asthma
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy
Source: International Congress 2016 – Clinical and molecular studies in asthma
Year: 2016
24-h efficacy and pharmacokinetics of tiotropium Respimat® 5 μg in patients with asthma
Source: International Congress 2015 – Immune mechanisms in the human lung
Year: 2015
Clinical effectiveness of anti-IgE therapy in allergic severe asthma
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Experience with omalizumab in patients with moderate and severe asthma
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Efficacy and safety of inhaled corticosteroids in combination with a long-acting beta2-agonist in asthmatic children under age 5
Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma
Year: 2016
Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed-dose combination in patients with COPD: A 1-year study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Efficacy of tiotropium Respimat® in adults with moderate asthma, by baseline LTRA use
Source: International Congress 2015 – Modulating the immune system in COPD and asthma
Year: 2015
Efficacy of carbamazepine in treatment of bronchial asthma
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Tiotropium respimat: Comparison of bronchodilator efficacy of 5 and 2.5 µg doses
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Pharmacokinetics, safety and tolerability of CHF5993 a triple pMDI in renal impaired patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
LATE-BREAKING ABSTRACT: Safety and tolerability of once-daily tiotropium Respimat® add-on therapy in children with moderate symptomatic asthma
Source: International Congress 2016 – Living with asthma around the globe
Year: 2016
Long-acting anticholinergics in the treatment of severe asthma with irreversible airway obstruction
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept